华森制药(002907.SZ)取得克唑替尼胶囊药品注册证书

Core Viewpoint - The company received approval from the National Medical Products Administration for its product, Crizotinib capsules, which has been in the Chinese market since 2013 and included in medical insurance since 2018, demonstrating over ten years of clinical application experience [1] Company Summary - Crizotinib capsules are primarily used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) and for patients with advanced NSCLC who are positive for ROS1 [1]